You are absolutely right, GILD bypassed these steps and are now being questioned about Rem without having solid trial data to defend themselves. Leronlimab is following the rules from the FDA and the rules of proving the drug without doubt. GILD is showing the world it's corner cutting is going to cost everyone with the Rem distraction. The effort and funds directed towards Rem would likely been spent better with drugs that actually have a chance. I do think that GILD would agree with this, they likely sped up the process to get it over with knowing Rem is not the answer. They could not just do nothing and they really do not have any alternatives. I think, a total guess, that GILD is looking to partner with others so they can be a part of solving this.